<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02254109</url>
  </required_header>
  <id_info>
    <org_study_id>1205.18</org_study_id>
    <nct_id>NCT02254109</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising of BEA 2180 BR in Japanese Healthy Male Volunteers</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising Inhalative Doses (50 μg, 100 μg and 200 μg q.d. for 14 Days) of BEA 2180 BR in Japanese Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to evaluate safety, tolerability, and pharmacokinetics of BEA 2180 BR in Japanese
      healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with abnormal findings in physical examination</measure>
    <time_frame>up to 28 days after last dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant changes in vital signs</measure>
    <time_frame>up to 28 days after last dose administration</time_frame>
    <description>Blood pressure and pulse rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant changes in 12-lead electrocardiogram (ECG)</measure>
    <time_frame>up to 28 days after last dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal changes in laboratory parameters</measure>
    <time_frame>up to 28 days after last dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 28 days after last dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of tolerability by the investigator on a 4-point scale</measure>
    <time_frame>28 days after last dose administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 648:00 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 648:00 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ)</measure>
    <time_frame>up to 648:00 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable concentration at tz)</measure>
    <time_frame>up to 648:00 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aeτ (amount of analyte that is eliminated in urine over a uniform dosing interval τ)</measure>
    <time_frame>up to 648:00 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>feτ (fraction of analyte eliminated in urine over a uniform dosing interval τ)</measure>
    <time_frame>up to 648:00 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)</measure>
    <time_frame>up to 648:00 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss (minimum concentration of the analyte in plasma at steady state)</measure>
    <time_frame>up to 648:00 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cpre,ss (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose)</measure>
    <time_frame>up to 648:00 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz,ss (terminal rate constant in plasma at steady state)</measure>
    <time_frame>up to 648:00 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2,ss (terminal half-life of the analyte in plasma at steady state)</measure>
    <time_frame>up to 648:00 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTih,ss (mean residence time of the analyte in the body at steady state after inhalation administration)</measure>
    <time_frame>up to 648:00 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F,ss (apparent clearance of the analyte in the plasma at steady state following extravascular multiple dose administration)</measure>
    <time_frame>up to 648:00 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration)</measure>
    <time_frame>up to 648:00 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio of the analyte in plasma based on Cmax (RA,Cmax)</measure>
    <time_frame>up to 648:00 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio of the analyte in plasma based on AUC (RA,AUC)</measure>
    <time_frame>up to 648:00 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio of the analyte in plasma based on Ae (RA,Ae)</measure>
    <time_frame>up to 648:00 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BEA 2180 BR - rising dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BEA 2180 BR - rising dose</intervention_name>
    <arm_group_label>BEA 2180 BR - rising dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy Japanese men:

             According to the results of a complete medical history, the physical examination,
             vital signs (blood pressure and pulse rate), 12-lead ECG, clinical laboratory tests

          2. Age ≥20 and ≤35 years

          3. Body mass index (BMI) ≥18.5 and ≤25 kg/m2

          4. Subjects must be able to inhale medication in a competent manner from the Respimat®

          5. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice (GCP)

        Exclusion Criteria:

          1. Any finding of the medical examination (including blood pressure, pulse rate and ECG)
             deviating from normal and of clinical relevance

          2. Any evidence of a clinically relevant concomitant disease

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          4. Surgery of the gastrointestinal tract (except appendectomy)

          5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          6. History of relevant orthostatic hypotension, fainting spells or blackouts

          7. Chronic or relevant acute infections

          8. History of relevant allergy/hypersensitivity including allergy to drug or its
             excipients

          9. Intake of drugs with a long half-life (&gt;24 hours) within one month or less than 10
             half-lives of the respective drug before drug administration or during the trial

         10. Use of prescription or non-prescription drugs within 10 days before drug
             Administration or during the trial. However, over-the-counter (OTC) drugs for external
             application (such as lubricant eye drops for contact lens, insect bite reliever) shall
             be allowed

         11. Participation in another trial with an investigational drug within four months before
             drug administration or during the trial

         12. Smoker (&gt;10 cigarettes or &gt;3 cigars or &gt;3 pipes/day)

         13. Inability to refrain from smoking during the trial

         14. Alcohol abuse (≥60 g/day: corresponds to ca. 3 large bottles of beer, 3 gous (ca. 540
             cc) of Japanese sake, 6 shots of whisky, 6 glasses of wine or 6 glasses of Japanese
             shochu, distilled alcoholic beverage)

         15. Drug abuse

         16. Blood donation (≥100 mL within four weeks before drug administration or during the
             trial)

         17. Excessive physical activities (within one week before drug administration or during
             the trial)

         18. Any laboratory value outside the reference range that is of clinical relevance

         19. Inability to comply with dietary regimen of trial site

             Exclusion criteria specific for this study:

         20. Occupational (professional) exposure to antimuscarinic substances (e.g., physician,
             nurse, pharmacist etc.; volunteers working for medical institutions, research
             institutions or herb gardens)

         21. History of glaucoma, urination difficulty (due to prostatic hyperplasia etc.)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2014</study_first_submitted>
  <study_first_submitted_qc>September 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2014</study_first_posted>
  <last_update_submitted>September 30, 2014</last_update_submitted>
  <last_update_submitted_qc>September 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

